175 related articles for article (PubMed ID: 32686745)
1. KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations.
Pantsar T
Sci Rep; 2020 Jul; 10(1):11992. PubMed ID: 32686745
[TBL] [Abstract][Full Text] [Related]
2. Understanding the influence of AMG 510 on the structure of KRAS
Li Y; Han L; Zhang Z
Comput Struct Biotechnol J; 2022; 20():1056-1067. PubMed ID: 35284050
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS
Zhuang H; Fan J; Li M; Zhang H; Yang X; Lin L; Lu S; Wang Q; Liu Y
Front Oncol; 2022; 12():915512. PubMed ID: 36033504
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition.
Huynh MV; Parsonage D; Forshaw TE; Chirasani VR; Hobbs GA; Wu H; Lee J; Furdui CM; Poole LB; Campbell SL
J Biol Chem; 2022 Aug; 298(8):102186. PubMed ID: 35753348
[TBL] [Abstract][Full Text] [Related]
5. Modeling receptor flexibility in the structure-based design of KRAS
Zhu K; Li C; Wu KY; Mohr C; Li X; Lanman B
J Comput Aided Mol Des; 2022 Aug; 36(8):591-604. PubMed ID: 35930206
[TBL] [Abstract][Full Text] [Related]
6. AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research.
Wu LL; Jiang WM; Liu ZY; Zhang YY; Qian JY; Liu Y; Huang YY; Li K; Li ZX; Ma GW; Xie D
Discov Oncol; 2023 Jun; 14(1):91. PubMed ID: 37284902
[TBL] [Abstract][Full Text] [Related]
7. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Canon J; Rex K; Saiki AY; Mohr C; Cooke K; Bagal D; Gaida K; Holt T; Knutson CG; Koppada N; Lanman BA; Werner J; Rapaport AS; San Miguel T; Ortiz R; Osgood T; Sun JR; Zhu X; McCarter JD; Volak LP; Houk BE; Fakih MG; O'Neil BH; Price TJ; Falchook GS; Desai J; Kuo J; Govindan R; Hong DS; Ouyang W; Henary H; Arvedson T; Cee VJ; Lipford JR
Nature; 2019 Nov; 575(7781):217-223. PubMed ID: 31666701
[TBL] [Abstract][Full Text] [Related]
8. Structures of N-terminally processed KRAS provide insight into the role of N-acetylation.
Dharmaiah S; Tran TH; Messing S; Agamasu C; Gillette WK; Yan W; Waybright T; Alexander P; Esposito D; Nissley DV; McCormick F; Stephen AG; Simanshu DK
Sci Rep; 2019 Jul; 9(1):10512. PubMed ID: 31324887
[TBL] [Abstract][Full Text] [Related]
9. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS
Mortier J; Friberg A; Badock V; Moosmayer D; Schroeder J; Steigemann P; Siegel F; Gradl S; Bauser M; Hillig RC; Briem H; Eis K; Bader B; Nguyen D; Christ CD
ChemMedChem; 2020 May; 15(10):827-832. PubMed ID: 32237114
[TBL] [Abstract][Full Text] [Related]
10. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
11. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
[TBL] [Abstract][Full Text] [Related]
12. NMR-Chemical-Shift-Driven Protocol Reveals the Cofactor-Bound, Complete Structure of Dynamic Intermediates of the Catalytic Cycle of Oncogenic KRAS G12C Protein and the Significance of the Mg
Gadanecz M; Fazekas Z; Pálfy G; Karancsiné Menyhárd D; Perczel A
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569478
[TBL] [Abstract][Full Text] [Related]
13. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
Zeng M; Lu J; Li L; Feru F; Quan C; Gero TW; Ficarro SB; Xiong Y; Ambrogio C; Paranal RM; Catalano M; Shao J; Wong KK; Marto JA; Fischer ES; Jänne PA; Scott DA; Westover KD; Gray NS
Cell Chem Biol; 2017 Aug; 24(8):1005-1016.e3. PubMed ID: 28781124
[TBL] [Abstract][Full Text] [Related]
14. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
15. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Covalent Inhibitor of KRAS
Lanman BA; Allen JR; Allen JG; Amegadzie AK; Ashton KS; Booker SK; Chen JJ; Chen N; Frohn MJ; Goodman G; Kopecky DJ; Liu L; Lopez P; Low JD; Ma V; Minatti AE; Nguyen TT; Nishimura N; Pickrell AJ; Reed AB; Shin Y; Siegmund AC; Tamayo NA; Tegley CM; Walton MC; Wang HL; Wurz RP; Xue M; Yang KC; Achanta P; Bartberger MD; Canon J; Hollis LS; McCarter JD; Mohr C; Rex K; Saiki AY; San Miguel T; Volak LP; Wang KH; Whittington DA; Zech SG; Lipford JR; Cee VJ
J Med Chem; 2020 Jan; 63(1):52-65. PubMed ID: 31820981
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
18. Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG-510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL-XL.
Kitazawa M; Miyagawa Y; Koyama M; Nakamura S; Hondo N; Miyazaki S; Muranaka F; Tokumaru S; Yamamoto Y; Ehara T; Kuroiwa M; Tanaka H; Komatsu D; Takeoka M; Soejima Y
Mol Clin Oncol; 2021 Jul; 15(1):148. PubMed ID: 34094546
[TBL] [Abstract][Full Text] [Related]
19. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
20. Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRAS
Luo L; Zheng T; Wang Q; Liao Y; Zheng X; Zhong A; Huang Z; Luo H
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]